These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12746255)

  • 1. Use of isoniazid for latent tuberculosis infection in a public health clinic.
    LoBue PA; Moser KS
    Am J Respir Crit Care Med; 2003 Aug; 168(4):443-7. PubMed ID: 12746255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    McNeill L; Allen M; Estrada C; Cook P
    Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
    Lardizabal A; Passannante M; Kojakali F; Hayden C; Reichman LB
    Chest; 2006 Dec; 130(6):1712-7. PubMed ID: 17166986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
    Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
    Menzies D; Long R; Trajman A; Dion MJ; Yang J; Al Jahdali H; Memish Z; Khan K; Gardam M; Hoeppner V; Benedetti A; Schwartzman K
    Ann Intern Med; 2008 Nov; 149(10):689-97. PubMed ID: 19017587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons.
    Lobato MN; Reves RR; Jasmer RM; Grabau JC; Bock NN; Shang N;
    Chest; 2005 Apr; 127(4):1296-303. PubMed ID: 15821208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
    Villarino ME; Scott NA; Weis SE; Weiner M; Conde MB; Jones B; Nachman S; Oliveira R; Moro RN; Shang N; Goldberg SV; Sterling TR; ;
    JAMA Pediatr; 2015 Mar; 169(3):247-55. PubMed ID: 25580725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents.
    Chang SH; Eitzman SR; Nahid P; Finelli ML
    J Infect Public Health; 2014; 7(2):145-52. PubMed ID: 24361084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts.
    Young H; Wessolossky M; Ellis J; Kaminski M; Daly JS
    Clin Infect Dis; 2009 Aug; 49(3):424-7. PubMed ID: 19548835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
    McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
    BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
    Stout JE; Engemann JJ; Cheng AC; Fortenberry ER; Hamilton CD
    Am J Respir Crit Care Med; 2003 Mar; 167(6):824-7. PubMed ID: 12446275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study.
    Chang AH; Polesky A; Bhatia G
    BMC Public Health; 2013 Sep; 13():894. PubMed ID: 24073620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
    Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
    Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic.
    Dobler CC; Marks GB
    PLoS One; 2012; 7(11):e48900. PubMed ID: 23139824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 19. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
    Churchyard G; Cárdenas V; Chihota V; Mngadi K; Sebe M; Brumskine W; Martinson N; Yimer G; Wang SH; Garcia-Basteiro AL; Nguenha D; Masilela L; Waggie Z; van den Hof S; Charalambous S; Cobelens F; Chaisson RE; Grant AD; Fielding KL;
    Ann Intern Med; 2021 Oct; 174(10):1367-1376. PubMed ID: 34424730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.